The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-11 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Peptic ulcers === Peptic ulcers may be treated with omeprazole. Infection with Helicobacter pylori can be treated by taking omeprazole, amoxicillin, and clarithromycin together for 7–14 days. Amoxicillin may be replaced with metronidazole in patients who are allergic to penicillin.
An advertising poster featuring a picture of Michelangelo's David is removed from the Glasgow Subway at the request of the owners of the advertising space because of its nudity. It is replaced with an edited version hiding the crotch region. 20 May – The Annual General Meeting of the General Assembly of the Church of Scotland hears that hundreds of churches may have to close as a result of falling numbers of attendees and income. 21 May – Ten people are injured, and two are taken to hospital, after a bus crashes into a bridge in Glasgow and has its roof torn off. 22 May The Scottish Government offers junior doctors in Scotland a 14.5% pay rise. Margaret Ferrier loses her appeal against a proposed 30 day ban from the House of Commons over her breach of COVID-19 rules in September 2020. 24 May Following a hearing at the High Court in Edinburgh, Rhys Bennett is sentenced to life imprisonment with a minimum of 24 years for the rape and murder of Jill Barclay as she walked home in Aberdeen in September 2022. A group of eight former SNP councillors in North Lanarkshire form a new political party, Progressive Change NL, which becomes North Lanarkshire Council's second largest opposition party. 25 May – Responding to the outcome of a review of Police Scotland, its chief constable, Sir Ian Livingstone, says the force is institutionally sexist, racist and discriminatory.
== Bibliography == NMR in Biological Research: Peptides and Proteins, American Elsevier Pub. Co, 1976 NMR of proteins and nucleic acids, Wiley, 1986 NMR In Structural Biology: A Collection Of Papers By Kurt Wuthrich, World Scientific Publishing Co Pte Ltd, 1995
In children, orthodontic treatment to expand the volume of the nasal airway, such as nonsurgical rapid palatal expansion, is common. Since the palatal suture is fused in adults, regular RPE using tooth-borne expanders cannot be performed. Mini-implant-assisted rapid palatal expansion (MARPE) has been recently developed as a non-surgical option for the transverse expansion of the maxilla in adults. This method increases the volume of the nasal cavity and nasopharynx, leading to increased airflow and reduced respiratory arousals during sleep. Changes are permanent with minimal complications.
Sources: en.wikipedia.org
==== Musculoskeletal and bone tissues ==== Musculoskeletal applications represent a commercially mature sector of tissue engineering, focusing on the repair of critical-sized bone defects, articular cartilage lesions, and volumetric muscle loss. For orthopedic bone regeneration, therapeutic approaches utilize osteoconductive and osteoinductive scaffolds composed of bioceramics (such as hydroxyapatite and beta-tricalcium phosphate), biodegradable polymers, or composite hydrogels. These matrices serve as physical frameworks that recruit endogenous mesenchymal stem cells (MSCs) and promote osteogenesis. A critical challenge in bone tissue engineering is achieving adequate neovascularization within the core of large scaffolds to prevent core necrosis before host capillary ingrowth occurs. Consequently, modern biomaterial designs often implement multi-scale porosity, integrating smaller voids for nutrient diffusion with macro-channels greater than 100 micrometers, to facilitate deep cellular infiltration, matrix mineralization, and functional host tissue integration.
Lawrence Livermore National Laboratory (LLNL) is a federally funded research and development center in Livermore, California, United States. Established in 1952, the laboratory is sponsored by the United States Department of Energy and administered privately by Lawrence Livermore National Security, LLC. The lab was originally established as the University of California Radiation Laboratory, Livermore Branch in 1952 in response to the detonation of the Soviet Union's first atomic bomb during the Cold War. It later became autonomous in 1971 and was designated a national laboratory in 1981. Lawrence Livermore Lab is primarily funded by the United States Congress and it is managed privately and operated by Lawrence Livermore National Security, LLC (a partnership of the University of California, Bechtel, BWX Technologies, Amentum, and Battelle Memorial Institute in affiliation with the Texas A&M University System). In 2012, the synthetic chemical element livermorium (element 116) first made in year 2000, was named after the laboratory. The Livermore facility was co-founded by Edward Teller and Ernest Lawrence, then director of the Radiation Laboratory at Berkeley.
APHL works with public health partners to build the foundation for quality testing, comprehensive standards and integrated public health laboratory systems. One of the initiatives, the Laboratory System Improvement Program, provides individual assessments of public health laboratory systems that include engaging stakeholders for system improvement, performance, implementation of strategies and continual evaluation. APHL also collaborates on the National Laboratory System project to build a public-private network of laboratories nationwide. APHL monitors trends in public health laboratory diagnostics, personnel and infrastructure in order to create quality assurance standards. By using these data points to benchmark individual labs against national norms, APHL is able to home in on key issues and help raise the standard of laboratory systems. Member labs have access to research and survey data online, which enables them to leverage new information quickly to identify promising strategies and practices.
and Canada, calcium is instead produced by reducing lime with aluminium at high temperatures. In this process, powdered high-calcium lime and powdered aluminum are mixed and compacted into briquettes for a high degree of contact, which are then placed in a sealed retort which has been evacuated and heated to ~1200°C. The briquettes release calcium vapor into the vacuum for about 8 hours, which then condenses in the cooled ends of the retorts to form 24-34 kg pieces of calcium metal, as well as some residue of calcium aluminate. High-purity calcium can be obtained by distilling low-purity calcium at high temperatures.
== Adverse effects == In about 0.1% of cases people have had anaphylactic reactions to lixisenatide and in about 0.2% of cases the drug has caused pancreatitis. Use with insulin or sulfonylurea may cause hypoglycemia. In some cases, people with no kidney disease have had acute kidney injury and in some people with existing kidney disease the condition has gotten worse. Because lixisenatide is a peptide people can and do develop an immune response to it that will eventually make the drug ineffective; people who have developed antibodies to lixisenatide tend to have more inflammation at the injection site. At least 5% of people had nausea, vomiting, diarrhea, headache, or dizziness after taking lixisenatide.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.